Multiple Myeloma Therapy Market is evolving as pharmaceutical companies and researchers continue to introduce new approaches for managing multiple myeloma. The treatment landscape has gradually moved beyond conventional chemotherapy toward more targeted and immune-based therapies.

Targeted therapy is an important component of the current market. These treatments are designed to act on specific biological mechanisms associated with cancer cells. Immunotherapy is also receiving significant attention because of its potential to use or strengthen the body's immune response against malignant cells.

CAR-T cell therapy and monoclonal antibody treatments represent notable areas of innovation. These technologies are contributing to the development of more personalized approaches and may provide additional options for patients whose disease has returned or become resistant to earlier treatments.

The market is also divided according to treatment stage, including initial treatment, relapsed treatment, and maintenance therapy. Each stage creates different requirements for medicines and supporting healthcare services.

WiseGuyReports estimates that the market could increase from USD 39.8 billion in 2025 to USD 75.0 billion by 2035, with a projected CAGR of 6.5% between 2026 and 2035.

As clinical research progresses, continued development of combination therapies, personalized medicine, and novel immunotherapies is expected to influence the future direction of the multiple myeloma treatment industry.